Breaking News Instant updates and real-time market news.

GS

Goldman Sachs

$218.66

6.91 (3.26%)

, CRL

Charles River

$72.91

1.35 (1.89%)

10:22
11/30/16
11/30
10:22
11/30/16
10:22

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) upgraded to Buy from Hold at Deutsche Bank with analyst Matt O'Connor saying leverage to higher rates is mostly reflected in bank stock prices following their post-election advance so far, but that higher loan growth and fee volumes from a stronger economy may not be. 2. Charles River upgraded to Equal Weight from Underweight at Barclays with analyst Douglas Tsao saying Charles River is the biggest beneficially of the increased biopharma R&D and views valuation as balanced at current levels. 3. Celanese (CE) upgraded to Buy from Neutral at Goldman with analyst Robert Koort saying he believes Celanese is poised to outperform given continued strong execution by management with focus on mix improvement, strong cash flow generation, and shareholder friendly deployment. 4. MAA (MAA) upgraded to Outperform from Market Perform at BMO Capital with analyst John Kim citing valuation. 5. Super Micro Computer (SMCI) upgraded to Buy from Neutral at DA Davidson with analyst Mark Kelleher saying he expects the company to report strong December quarter results and predicts that it will benefit from the rollout of Intel's (INTC) Sky Lake product and the strong growth of its own storage product. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

GS

Goldman Sachs

$218.66

6.91 (3.26%)

CRL

Charles River

$72.91

1.35 (1.89%)

CE

Celanese

$79.61

2.45 (3.18%)

MAA

MAA

$92.92

-0.89 (-0.95%)

SMCI

Super Micro Computer

$26.10

-0.25 (-0.95%)

  • 01

    Dec

  • 06

    Dec

  • 07

    Dec

  • 08

    Feb

  • 09

    Feb

GS Goldman Sachs
$218.66

6.91 (3.26%)

11/30/16
11/30/16
UPGRADE

Buy
Deutsche ups Goldman Sachs to Buy, says stronger economy not yet priced in
As previously reported, Deutsche Bank analyst Matt O'Connor upgraded Goldman Sachs (GS) to Buy from Hold, offering the opinion that leverage to higher rates is mostly reflected in bank stock prices following their post-election advance so far, but that higher loan growth and fee volumes from a stronger economy may not be. After having updated his earnings models to more closely reflect a combination of stronger economic growth, higher interest rates and lower regulations and tax rates, O'Conner said Goldman is now one of his top, listing Huntington Bancshares (HBAN) and Wells Fargo (WFC) as his top large regional bank choices.
11/29/16
DBAB
11/29/16
UPGRADE
DBAB
Buy
Goldman Sachs upgraded to Buy from Hold at Deutsche Bank
11/29/16
KBWI
11/29/16
UPGRADE
Target $240
KBWI
Outperform
Goldman Sachs upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Goldman Sachs to Outperform saying the company should benefit more than peers from a better trading environment. The analyst raised his price target for the shares to $240 from $185.
11/29/16
11/29/16
DOWNGRADE
Target $201

Neutral
Goldman Sachs downgraded to Neutral on valuation at Nomura
As previously reported, Nomura downgraded Goldman Sachs to Neutral from Buy and maintained its $201 price target. Analyst Steven Chubak said risk/reward is more balanced given an already low tax rate, lower asset sensitivity, weaker excess capital, higher risk of multiple rebasing, and heavier international exposure.
CRL Charles River
$72.91

1.35 (1.89%)

11/30/16
LEHM
11/30/16
UPGRADE
Target $77
LEHM
Equal Weight
Charles River upgraded to Equal Weight from Underweight at Barclays
10/19/16
JEFF
10/19/16
DOWNGRADE
Target $79
JEFF
Hold
Quintiles downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Quintiles (Q) to Hold citing concern over the revenue synergy targets from the IMS merger. Windley notes that his firm's survey work indicates sponsors remain skeptical of IMS data's value in speeding clinical trial execution. He lowered his price target for the shares to $79 from $80. The analyst's top picks in Pharmaceutical Services are Charles River (CRL), INC Research (INCR) and PRA Health (PRAH).
11/03/16
JEFF
11/03/16
NO CHANGE
JEFF
Charles River outlook still positive despite revenue miss, says Jefferies
After Charles River reported lower than expected Q3 revenue, Jefferies analyst David Windley blames the miss on delayed studies. The analyst expects the company's organic growth to come in at high single percentage digits in Q4, and he thinks that it will benefit from "steady, even improving outsourcing trends" going forward. He sees the Q3 results as "transient" and keeps a Buy rating.
11/30/16
11/30/16
UPGRADE
Target $77

Equal Weight
Charles River upgraded to Equal Weight from Underweight at Barclays
As previously reported, Barclays upgraded Charles River to Equal Weight and raised its price target to $77 from $65. Analyst Douglas Tsao said Charles RIver is the biggest beneficially of the increased biopharma R&D and views valuation as balanced at current levels.
CE Celanese
$79.61

2.45 (3.18%)

11/30/16
GSCO
11/30/16
UPGRADE
GSCO
Buy
Celanese upgraded to Buy from Neutral at Goldman
10/06/16
KEYB
10/06/16
INITIATION
KEYB
Overweight
Celanese initiated with an Overweight at KeyBanc
11/30/16
11/30/16
UPGRADE
Target $92

Buy
Celanese upgraded to Buy on growth profile at Goldman
As previously reported, Goldman upgraded Celanese to Buy from Neutral and raised its price target to $92 from $83. Analyst Robert Koort believes Celanese is poised to outperform given continued strong execution by management with focus on mix improvement, strong cash flow generation, and shareholder friendly deployment.
10/06/16
KEYB
10/06/16
INITIATION
Target $80
KEYB
Overweight
Celanese initiated with an Overweight at KeyBanc
KeyBanc analyst Micahel Sison initiated Celanese with an Outperform and an $80 price target. The analyst said Celanese has an operating strategy that can generate steady growth, high margins and top tier returns in the specialty chemical sector.
MAA MAA
$92.92

-0.89 (-0.95%)

10/20/16
JMPS
10/20/16
UPGRADE
JMPS
Outperform
MAA upgraded on valuation, M&A track record at JMP Securities
As noted earlier, JMP Securities upgraded MAA to Outperform from Market Perform. Analyst Aaron Hecht cited valuation and what he sees as the company's successful M&A track record as reasons for the upgrade. Target $105.
10/20/16
10/20/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Express (AXP) upgraded to Neutral from Underperform at BofA/Merrill with the firm's analyst saying the third quarter earnings report points to better than expected billings and higher net interest income and should result in improved sentiment. 2. Kinder Morgan (KMI) upgraded to Outperform from Neutral at Credit Suisse, to Buy from Hold at Stifel, and to Outperform from Peer Perform at Wolfe Research. 3. MAA (MAA) upgraded to Buy from Hold at Jefferies and to Outperform from Market Perform at JMP Securities. 4. Banc of California (BANC) upgraded to Buy from Neutral at DA Davidson with analyst Gary Tenner citing a steep recent selloff that culminated with Tuesday's decline sparked by a negative Seeking Alpha post. The bank has refuted the most meaningful claim in the recent article and its just-released earnings beat expectations, driven by higher fee income levels, Tenner tells investors. 5. DragonWave (DRWI) upgraded to Hold from Sell at Desjardins with analyst Maher Yaghi saying the Sprint (S) contract announcement may be large enough to bring operations back into a cash neutral position. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
BMOC
11/30/16
UPGRADE
BMOC
Outperform
MAA upgraded to Outperform from Market Perform at BMO Capital
11/30/16
BMOC
11/30/16
UPGRADE
BMOC
Outperform
MAA upgraded on performance, valuation at BMO Capital
As noted earlier, BMO Capital upgraded MAA to Outperform from Market Perform. Analyst John Kim upgraded the stock based on valuation. He says that the multifamily REIT's discount to its peers is too large, since its "EVA, organic growth, and balance sheet strength are at the high end of the sector." Additionally, he believes that MAA's acquisition of Post and its inclusion in the S&P 500 will cause the discount versus its peers to diminish Target to $104 from $102.
SMCI Super Micro Computer
$26.10

-0.25 (-0.95%)

07/28/16
07/28/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cray (CRAY) initiated with an Overweight at Pacific Crest. 2. Fate Therapeutics (FATE) assumed with a Buy at H.C. Wainwright. 3. Super Micro Computer (SMCI) initiated with a Sector Weight at Pacific Crest. 4. Stamps.com (STMP) re-initiated with a Buy at Roth Capital. 5. Ormat Technologies (ORA) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/05/16
ROTH
08/05/16
DOWNGRADE
Target $22.5
ROTH
Neutral
Super Micro Computer downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Brian Alger downgraded Super Micro Computer to Neutral from Buy and lowered his price target on the shares to $22.50 from $40, citing the limited stock upside from current trading levels and his uncertainty toward the competitive landscape.
11/30/16
DADA
11/30/16
UPGRADE
DADA
Buy
Super Micro Computer upgraded to Buy from Neutral at DA Davidson
11/30/16
DADA
11/30/16
UPGRADE
DADA
Buy
Super Micro Computer upgraded on multiple positive catalysts at DA Davidson
As noted earlier, DA Davidson upgraded Super Micro Computer (SMCI) to Buy from Neutral. Analyst Mark Kelleher expects the company to report strong December quarter results and predicts that it will benefit from the rollout of Intel's (INTC) Sky Lake product and the strong growth of its own storage product. Target to $32 from $25.

TODAY'S FREE FLY STORIES

ZYNE

Zynerba

$22.10

0.27 (1.24%)

07:59
02/24/17
02/24
07:59
02/24/17
07:59
Initiation
Zynerba initiated  »

Zynerba initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

NGVT

Ingevity

$54.35

-2.06 (-3.65%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Recommendations
Ingevity analyst commentary  »

Ingevity weakness creates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Earnings
U.S. Cellular sees FY17 revenue $3.8B-$4B, consensus $4.05B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BSX

Boston Scientific

$24.48

-0.68 (-2.70%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Recommendations
Boston Scientific analyst commentary  »

Selloff in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 17

    Mar

  • 04

    May

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Earnings
U.S. Cellular reports Q4 EPS (7c), consensus (25c) »

Reports Q4 revenue $991M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Hot Stocks
Bristol-Myers' Abatacept designated as orphan treatment of IIM »

Bristol-Myers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:56
02/24/17
02/24
07:56
02/24/17
07:56
Earnings
Telephone and Data sees FY17 revenue $5.015B-$5.265B, consensus $5.29B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Hot Stocks
Janssen's Stelara designated as orphan treatment of pediatric ulcerative colitis »

Janssen's Stelara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

NVRO

Nevro

$94.25

-2.26 (-2.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Recommendations
Nevro analyst commentary  »

Nevro price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSPP

RSP Permian

$40.36

-0.55 (-1.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
RSP Permian to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 20

    Mar

ETN

Eaton

$72.12

-0.38 (-0.52%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
Eaton to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:54
02/24/17
02/24
07:54
02/24/17
07:54
Earnings
Telephone and Data reports Q4 EPS (5c), consensus (5c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Hot Stocks
Telephone and Data raises quarterly dividend to 15.5c per share »

Payment will be made on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TERP

TerraForm Power

$11.40

-0.16 (-1.38%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Earnings
TerraForm Power reports Q3 EPS (29c), consensus (16c) »

Reports Q3 revenue $178M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOO

Steven Madden

07:50
02/24/17
02/24
07:50
02/24/17
07:50
Recommendations
Steven Madden analyst commentary  »

Steven Madden price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEG

PSEG

$44.25

-0.02 (-0.05%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Earnings
PSEG reports Q4 adjusted EPS 54c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Apple analyst commentary  »

Apple average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

SPLK

Splunk

$64.90

-0.08 (-0.12%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Splunk analyst commentary  »

Splunk should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PSO

Pearson

$8.10

0.22 (2.79%)

07:48
02/24/17
02/24
07:48
02/24/17
07:48
Hot Stocks
Pearson to rebase dividend from 2017 onwards »

Pearson said: " As…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSO

Pearson

$8.10

0.22 (2.79%)

07:47
02/24/17
02/24
07:47
02/24/17
07:47
Earnings
Pearson backs 2017 outlook, says early trading in line with expectations »

Pearson said its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$50.85

-0.75 (-1.45%)

07:46
02/24/17
02/24
07:46
02/24/17
07:46
Upgrade
Methanex rating change  »

Methanex upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PSO

Pearson

$8.10

0.22 (2.79%)

07:45
02/24/17
02/24
07:45
02/24/17
07:45
Earnings
Pearson reports FY16 adjusted EPS 58.8p vs. 70.3p last year »

Reports FY16 sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEX

Terex

$29.91

-1.5 (-4.78%)

07:44
02/24/17
02/24
07:44
02/24/17
07:44
Initiation
Terex initiated  »

Terex reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 07

    Mar

CERN

Cerner

$55.39

0.02 (0.04%)

07:43
02/24/17
02/24
07:43
02/24/17
07:43
Downgrade
Cerner rating change  »

Cerner downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

RLGY

Realogy

$27.41

0.06 (0.22%)

07:43
02/24/17
02/24
07:43
02/24/17
07:43
Hot Stocks
Realogy announces new $300M share repurchase program »

"Our 2016 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.